Don't know if you caught it, but Shea seems to think 2012 is a reasonable timeframe for an FoB deal for MNTA (#msg-69795377 ).
>>Unidentified Analyst
I think all of us appreciate how difficult it is to consummate a deal, and making projections about timing is kind of fraught with risk. But given that time is of the essence and we are kind of marching on and you’re talking about patents that are not so far away – certainly as it relates to clinical development timelines, is 2012 – is that a reasonable expectation for the market to see a deal in this regard for Momenta?
Rick Shea
I think for us, we agree entirely with what you’re saying. And for us, sooner is better than later. We’re certainly motivated to get something done in more of a near-term timeframe as you’re describing.<<
This is a response to a somewhat garbled question, and can be parsed in a few ways. But since Shea did not himself say 2012, I think Dew's "timing uncertain" is still the most accurate summation. I still think partners are looking for a bit more clarity from the FDA before committing to a broad, expensive deal.
Perhaps a poll on when we expect the partnership? Maybe we did one already. I'd vote for late Q412.
Market Data 
Markets 
AI
